Prenetics Global signs "transformational" $200mln deal to create cancer screening JV | News Direct

Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

Prenetics Global Ltd
News release by Prenetics Global Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | June 30, 2023 08:00 AM Eastern Daylight Time

 

Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

 

Contact Details

 

Proactive United States

 

Proactive United States

 

+1 347-449-0879

 

action@proactiveinvestors.com